Search

WASHINGTON, DC — The U.S. Food and Drug Administration, in collaboration with major implantable pacemaker and ICD manufacturers, demonstrated the effects of emissions from radio frequency identification (RFID) readers on common implantable cardiac devices. According to research published in the January edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, the observed effects may cause increasing complications as RFID use expands in the medical device field.

WASHINGTON, DC — March 1, 2010 – Analysis of ICD patients enrolled in four different trials found patients with life-threatening ventricular arrhythmias (VA) treated only with antitachycardia pacing (ATP) have higher survival rates than VA patients who experienced at least one shock-treated episode. According to research published in the March edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, 80.2% of VA episodes were successfully treated with ATP-only therapy from an ICD.

WASHINGTON, July 1, 2010 — New large meta-analysis from five primary prevention randomized implantable cardioverter-defibrillator (ICD) studies shows a smaller impact of Sudden Cardiac Death (SCD) on overall mortality in women.  According to research published in the July edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, women in primary prevention ICD trials have the same overall mortality as men, while experiencing significantly less appropriate ICD interventions. With more than 1,600 women, this meta-analysis includes the largest cohort of women to date.  

Lack of awareness and treatment of sudden cardiac arrest (SCA) puts African Americans at greater risk of death from the condition, according to a new national survey released today by the Heart Rhythm Society (HRS). The survey findings uncovered significant perception gaps between healthcare providers and consumers when it comes to understanding the condition, its symptoms, risk factors and treatments. Responsible for more than 350,000 U.S. deaths each year, SCA occurs when the heart suddenly and unexpectedly stops beating. Approximately 95 percent of SCA cases result in death; however, it is proven most deadly in African Americans.

The meeting will present current and future management on sudden cardiac death, new drug and ablation treatment for atrial fibrillation, pacing and ICD advances, cardiac resynchronization techniques, remote patient monitoring, and advances in neuromodulation for heart failure and hypertension. The well received certificate Cardiac Rhythm Management Course will continue, and new courses on EPS/ECG added.

WASHINGTON, DC — New research reveals that abandoning a nonfunctioning lead in an ICD patient is safe and does not pose a clinically significant risk of complication. The lead is the wire placed in the heart that transmits the heart's electrical signals to the defibrillator for interpretation. The new study published in the January edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, suggests that the practice of abandoning nonfunctioning leads does not result in additional risk to the patient and lead extraction should be reserved for cases of system infection or when large numbers of leads have been abandoned.

Defibrillation, or shock, can be the only way to stop certain heart arrhythmias, or irregular heartbeats, before they kill. If the heart beats too quickly, the chambers, or ventricles, will not have enough time to fill with blood and pump blood to the rest of the body, which can cause death. For people at high risk for the deadliest forms of arrhythmias – called ventricular tachycardia and ventricu­lar fibrillation – an internal “shocking” device may be the best protection against sudden cardiac arrest (SCA).

An update to this document was published in 2017 and is available at this link.  

May 13, 2009 — An international team of device and lead management experts from North America and Europe wrote this 2009 consensus document on the management of leads in patients with cardiovascular implantable electronic devices (CIEDs). Central to this effort was a focus on transvenous lead extraction, including standards for training and for the evaluation of new tools and techniques.

May 5, 2011 — Developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA) and the Society of Thoracic Surgeons (STS), a diverse panel of experts in pacemaker and defibrillator management focused on medical procedures that might interfere with Cardiovascular Implantable Electronic Devices (CIEDs) function.

May 9, 2014 - This expert consensus statement was written by experts and developed in partnership with and endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA); and in collaboration with and endorsed by the Heart Failure Society of America (HFSA) and the Society of Thoracic Surgeons (STS).  Endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS) and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.

May 13, 2015 - The current document is developed from the foundations established by the 2008 HRS Consensus Statement as well as the 2012 International Society for Holter and Noninvasive Electrocardiography and European Heart Rhythm Association’s Expert Consensus Statement on Remote Monitoring of CIEDs.  The goals of follow-up, definition of hardware, and personnel remain the same and will not be covered in this document except where evolution of remote technologies and responsibilities has occurred. The current document provides new recommendations based on data published since 2008, endorsing the need to maintain consistent follow-up, and outlining the limitations of strictly in-person methods.

The topic covered by this document includes the monitoring of CIEDs with a description of the technology, indications for use, personnel involved in monitoring and the frequency and types of monitoring events. Also covered are issues in regard to data management, regulatory environments, reimbursement and ethical considerations in respect to device inactivation.

This document has been retired and replaced by 2015 "HRS Expert Consensus Statement on Remote Interrogation and Monitoring for Cardiovascular Electronic Implantable Devices."

May 14, 2010 - This document was developed in collaboration with and endorsed by the American College of Cardiology (ACC), the American Geriatrics Society (AGS), the American Academy of Hospice and Palliative Medicine (AAHPM); the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), and the Hospice and Palliative Nurses Association (HPNA). It focuses on patients nearing the end of life and addresses patients who have made a decision for CIED deactivation at other times, as well as the rights and responsibilities of clinicians (and others, such as industry-employed allied professionals) who may not wish to perform deactivation.

November 19, 2015 - The benefits and risks of ICD therapy for patients are directly impacted by the programming and surgical decisions made by the clinician. This expert consensus statement systemically describes four important clinical issues and addresses programming of: bradycardia mode and rate, tachycardia detection, tachycardia therapy, and intraprocedural testing of defibrillation efficacy.

December 13, 2005 — This is the first study designed to look at the relation between patient outcomes and physicians'/hospitals' volume of cardioverter-defibrillator implantation to determine whether implantation should be limited to physicians with high procedural volume.